Anavex Life Sciences shares surge 25.34% after-hours following positive Blarcamesine data presentation at CTAD conference and strong Q4 earnings.

Anavex Life Sciences surged 25.34% in after-hours trading following the presentation of Blarcamesine data at the 18th CTAD Alzheimer’s conference, which highlighted cognitive resilience in Phase IIb/III trials, and the release of Q4 2025 earnings demonstrating a strong cash position. The stock’s rally aligns with renewed optimism over regulatory pathways and clinical progress, including positive topline results from a Phase 2 study of ANAVEX®3-71 for schizophrenia. These developments, coupled with a business update emphasizing long-term financial stability, likely drove the significant after-hours increase.